(November 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its public offering of $250 million aggregate principal amount of its 4.250 percent senior notes due January 12, 2011 and $250 million aggregate principal amount of its 5.125 percent senior notes due January 12, 2017, under its existing shelf registration statement.

Boston Scientific plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

The joint bookrunners for the offering were Merrill Lynch & Co., UBS Investment Bank and Wachovia Capital Markets LLC.

Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with capital markets, new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.